http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110872258-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-86 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-86 |
| filingDate | 2018-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110872258-B |
| titleOfInvention | Preparation process of prostate cancer drug enzalutamide |
| abstract | The present invention provides aA process for preparing Enzalutamide as the medicine of prostatic cancer includes such steps as catalytic nucleophilic substitution reaction between N-methyl-4-bromo-2-fluoro-benzamide and 2-aminoisobutyric acid under alkaline condition to obtain 2- (3-fluoro-4- (methylcarbamoyl) phenylamino) -2-methylpropanoic acid, esterification reaction to obtain 2-methoxyethyl 2- ((3-fluoro-4- (methylcarbamoyl) phenyl) amino) -2-methylpropionate, cyclization reaction between said product and 2-trifluoromethyl-4-isothiocyanatobenzonitrile to obtain 4- (3- (4-cyano-3-trifluoromethyl) phenyl) -5, 5-dimethyl-4-oxo-2-thioimidazol-1-yl) -2-fluoro-N-methylbenzamide, enzalutamide. The method provided by the invention overcomes the main defects in the prior art, avoids using high-toxicity reagents such as methyl iodide and the like, and has the advantages of mild reaction conditions, convenience and simplicity in post-treatment, improvement of total yield, reduction of reaction time, reduction of preparation cost, greenness and environmental friendliness, and suitability for industrial mass production. |
| priorityDate | 2018-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 77.